Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 125,990

Document Document Title
WO/2017/164349A1
Provided is a medicinal composition comprising a stable PEG antihuman NGF antibody Fab' fragment wherein the formation of a degradation product, multimer, acidic analog, basic analog and insoluble foreign matters is suppressed. The medic...  
WO/2017/162674A1
The present invention relates to a compound of formula (I) wherein P1, P3, P4 and P5 are amino acid residues. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It ...  
WO/2017/165747A1
Compositions and methods for treating, inhibiting, and/or preventing pain, particularly neuropathic pain, are provided.  
WO/2017/165458A1
The invention is directed to methods for diagnosis and differentiation of neurodegenerative diseases (NDs), by quantifying miRNAs in bodily fluids.  
WO/2017/165237A1
Provided herein is a neural sleep circuit that includes: a first subtype of neurons in a preoptic area (POA) of the brain, wherein neurons of the first subtype (a) are gamma aminobutyric acidproducing (GABAergic), and (b) project to a tu...  
WO/2017/162536A1
Prodrugs of vortioxetine are provided  
WO/2017/157326A1
Provided is a nerve growth factor mutant, wherein same is an amino acid sequence as shown by any one of SEQ ID No: 3 to SEQ ID No: 21 in the sequence listing. The advantage of the nerve growth factor mutant lies in that the mutation of a...  
WO/2017/160864A1
The present invention includes a method of protecting or treating neural cells from degeneration comprising: identifying a neural cell in need of protection from at least one of radical oxidative stress, increased mitochondrial biogenesi...  
WO/2017/157325A1
The present invention relates to the field of biopharmaceuticals and provides a fusion protein comprising a nerve growth factor (NGF) and a preparation method and use thereof. The fusion protein has a general formula represented by A-B o...  
WO/2017/161370A1
Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.  
WO/2017/157873A1
The present invention relates to a compound of formula (I) and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of cer...  
WO/2017/159484A1
[Problem] To provide an agent for inhibiting aggregation of tau and/or amyloid β. [Solution] A compound represented by formula (I) or a salt thereof. This compound is used in therapy, diagnosis, and symptom alleviation and in prevention...  
WO/2017/158093A1
The present invention relates to a nanoparticle composition comprising PLGA derivatives and a lipid. The composition is suitable for medical use. Particularly, the present invention relates to a delivery system for delivery of drugs, in ...  
WO/2017/161172A1
Provided herein are methods, compounds, and compositions for reducing expression of KEAP1 in animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate oxidative stress or a disease, disorder or ...  
WO/2017/160622A1
The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of (1r,1'R,4R)-4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)py...  
WO/2017/160922A1
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.  
WO/2017/160925A1
Disclosed herein are compounds of Formulae (I), and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.  
WO/2017/160552A1
Disclosed herein novel dopamine D3 receptor selective antagonists/partial agonists compounds with high affinity and metabolic stability useful for the treatment of psychiatric and neurological disorders and as research and diagnostic too...  
WO/2017/157929A1
The present invention relates to quinoline compounds of formula (I) wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their...  
WO/2017/161137A1
The invention provides methods and compositions for treating a subject with a neurodegenerative disorder, where the subject has a sphingotype indicative that the subject is likely to respond to treatment with an activator of β-glucocere...  
WO/2017/159700A1
A non-tubular material for nerve regeneration induction use, which can be used for the regeneration of a damaged part in a nerve, and which comprises: (A) a crosslinked substance produced by crosslinking a low-endotoxin bioabsorbable pol...  
WO/2017/160711A1
The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure ...  
WO/2017/158064A1
The present disclosure provides for methods for treating a subject having a disease or disorder associated with the accumulation of amyloid beta, comprising administering to the subject a BACE inhibitor and an antibody or antigen-binding...  
WO/2017/161017A1
The invention provides -opioid receptor agonists that are analgesic agents and that promote diminished side effects relative to a comparably effective dose of morphine. The side effects that are absent or attenuated include one or more o...  
WO/2017/159380A1
The purpose of the present invention is to provide a method for producing an upper motor neuron from a pluripotent stem cell, and a pluripotent stem cell which can be converted into an upper motor neuron. This method comprises a step for...  
WO/2017/161256A1
The disclosure relates to systems and methods for assessing and determining the likelihood or prognosis of Alzheimer's disease or mild cognitive impairment in a subject.  
WO/2017/158132A1
Embodiments of the present disclosure relate to novel methods for treating diseases using nicotinic acid riboside.  
WO/2017/158213A1
The present invention relates to a carbon nanotube coating for use as a system for anchoring micro-nanoscale devices with therapeutic activity to the cell membrane and for conveying these devices to the cytosol. Also disclosed is a compo...  
WO/2017/161155A1
Methods of preventing or treating Parkinson's disease in subjects are described where drugs are administered to subjects in effective amounts to cause the farnesylation of PARIS and the enhanced expression of PGC-1 a in the brain. These ...  
WO/2017/160926A1
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.  
WO/2017/160930A1
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.  
WO/2017/152821A1
Disclosed are an isoquinoline compound, and intermediates, a preparation method and an application thereof. The isoquinoline compound of the present invention has a structure as represented by formula I, wherein R1 and R2 are each indepe...  
WO/2017/155396A1
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosa...  
WO/2017/152254A1
A method for preventing or reducing the risk of perinatal or neonatal morbidity and mortality caused by antenatal inflammation in humans is described. This method is based on the administration of a compound of formula I or a pharmaceuti...  
WO/2017/155578A1
The present specification provides methods of treating a muscular disorder with a combination of a RXR agonist and a thyroid hormone.  
WO/2017/156395A1
This invention pertains to the identification of antibody mediated epitope mimics and applications of the identification of said mimic peptides in the design of biotherapeutics and vaccines.  
WO/2017/154016A1
The present invention relates to novel crystalline polymorphs of 1 -[2-(2,4-dimethyl- phenylsulfanyl)-phenyl] -piperazine hydrobromide represented by the following structural formula- la and process for preparation thereof.  
WO/2017/153995A1
A method for treating a patient suffering from a neuronal hypo-kinetic disease or a neuronal hyper-kinetic disease by modulating neuronal activity in the: internal globus pallidus (GPi), in the anterior motor thalamus and/or in the exter...  
WO/2017/153982A1
A method of enhancing the myelinating activity of oligodendrocytes or progenitors thereof is disclosed. The method comprises contacting the oligodendrocytes or the progenitors with an agent that binds to G Protein-Coupled Receptor 37 (GP...  
WO/2017/155395A1
The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA...  
WO/2017/152857A1
Disclosed in the present invention are an indoleamine-2,3-dioxygenase inhibitor and a preparation method therefor. The structure of the inhibitor of the present invention is shown in general formula (I), wherein the definitions of X, R1,...  
WO/2017/152655A1
Provided is a traditional Chinese medicine preparation for treating qi and blood deficiency-type generalized anxiety disorder. The medicinal raw materials thereof comprise spina date seed, angelica sinensis, radix paeoniae alba, radix re...  
WO/2017/153601A1
The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synucl...  
WO/2017/153829A1
The invention relates to a saffron extract comprising crocins and crocetins, for use in the treatment of sleep disorders in humans. According to the invention, the saffron extract comprises at least 2% by weight of crocins relative to th...  
WO/2017/153956A1
The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition ...  
WO/2017/153834A1
Provided herein are methods of treating a CDKL5 deficiency with tideglusib or a derivative thereof.  
WO/2017/155050A1
Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity. A compound represented by formula (I) [wherein each symbol is as defined in the description] or a salt thereof has a cholinergic m...  
WO/2017/154675A1
The agent for treating Fabry disease, analgesic for external use and perspiration accelerator according to one embodiment of the present invention comprise rapamycin or a rapamycin derivative.  
WO/2017/153957A1
The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for use in the treatment of a neurological di...  
WO/2017/154865A1
The present invention provides an ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which comprises γ-tocopherol and/or equol.  

Matches 101 - 150 out of 125,990